Is Ceapro Inc. a Buy? The Stock Rises Again


 Is Ceapro Inc. a Buy? The Stock Rises Again

The stock of Ceapro Inc. (CVE:CZO) is a huge mover today! About 72,360 shares traded hands. Ceapro Inc. (CVE:CZO) has risen 6.00% since September 19, 2016 and is uptrending. It has outperformed by 0.46% the S&P500.
The move comes after 9 months positive chart setup for the $128.91M company. It was reported on Oct, 19 by We have $5.44 PT which if reached, will make CVE:CZO worth $253.95 million more.

More notable recent Ceapro Inc. (CVE:CZO) news were published by: which released: “Ceapro Inc. Provides 2015 Business Highlights and 2016 Business Outlook” on April 18, 2016, also with their article: “Ceapro Inc. Announces Brokered Private Placement” published on June 09, 2016, published: “Ceapro Inc. Awarded Research Grant from German-Canadian Centre for Innovation …” on September 21, 2016. More interesting news about Ceapro Inc. (CVE:CZO) were released by: and their article: “Ceapro Inc. Presents Its PGX Technology at the 15th European Meeting on …” published on May 09, 2016 as well as‘s news article titled: “Ceapro Inc. Reports Second Quarter 2016 Financial and Operational Results” with publication date: August 24, 2016.

Ceapro Inc. is a Canada-based growth-stage biotechnology company. The company has a market cap of $128.91 million. The Company’s primary business activities relate to the development and commercialization of natural products for personal care, cosmetic, human and animal health industries using technology, natural and renewable resources. It has a 15.21 P/E ratio. The Company’s products include a commercial line of natural active ingredients, including beta glucan, avenanthramides , oat powder, oat oil, oat peptides and lupin peptides, which are marketed to the personal care, cosmetic, medical and animal health industries, and Veterinary therapeutic products, including an oat shampoo, an ear cleanser and a dermal complex/conditioner, which are manufactured and marketed to veterinarians in Japan and Asia.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Reply